ID: MRFR/Pharma/5129-HCR | 85 Pages | Author: Rahul Gotadki | June 2023
Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porterβs Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Bleeding disorders Treatment Market, by Type
6.1 Introduction
6.2 Hemophilia A
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.3 Hemophilia B
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.4 Von Willebrand Disease (vWD)
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
6.5 Others
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
Chapter 7. Global Bleeding disorders Treatment Market, by Drug Class
7.1 Introduction
7.2 Plasma-Derived Coagulation Factor Concentrates Market
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
7.3 Global Recombinant Coagulation Factor Concentrate Market
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
7.4 Global Others Bleeding Disorders Treatment Market
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
Chapter 8. Global Bleeding disorders Treatment Market, by Treatment
8.1 Introduction
8.2 Desmopressin (DDAVP)
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.3 Hormone Replacement Therapy
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.4 Contraceptives
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.5 Anti-Fibrinolytic/Clot-Stabilizing Drugs
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.6 Fibrin Sealants
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.6 Drugs applied to cuts
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
8.6 Pipeline Analysis (Phase I, Phase II and Phase III Clinical Trials)
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
Chapter 9. Global Bleeding disorders Treatment Market, by End-Users
9.1 Introduction
9.2 Hospitals
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
9.3 Clinics
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
9.4 Research Institutes
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
9.5 Others
Market Estimates & Forecast, by Region, 2020β2027
Market Estimates & Forecast, by Country, 2020β2027
Chapter 10. Global Bleeding disorders Treatment Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
Chapter 12. Company Profiles
12.1 Shire Plc
12.1.1 Company Overview
12.1.2 Type Overview
12.1.3 Financials Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Bayer Pharmaceuticals
12.2.1 Company Overview
12.2.2 Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
10.2.5 SWOT Analysis
12.3 Novo Nordisk A/S
12.3.1 Company Overview
12.3.2 Type Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Pfizer Inc.
12.4.1 Company Overview
12.4.2 Technology/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Biogen Idec
12.5.1 Company Overview
12.5.2 Type Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 CSL Behring
12.6.1 Company Overview
12.6.2 Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Grifols
12.7.1 Overview
12.7.2 Type Overview
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Octapharma
12.8.1 Overview
12.8.2 Type/ Technology Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Sun Pharmaceutical Industries Ltd.
12.9.1 Overview
12.9.2 Type Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 BDI Pharma
12.10.1 Overview
12.10.2 Type Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Ferring Pharmaceuticals
12.11.1 Overview
12.11.2 Type Overview
12.11.3 Financials
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Others
12.12.1 Overview
12.12.2 Type Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
Chapter 13. MRFR Conclusion
13.1 Key Findings
13.1.1 From CEOβs Viewpoint
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Predictions for the Bleeding Disorders Treatment Industry
Chapter 14. Appendix
LIST OF TABLES
Table 1 Global Bleeding disorders Treatment Synopsis, 2020β2027
Table 2 Global Bleeding disorders TreatmentEstimates and Forecast, 2020β2027 (USD Million)
Table 3 Global Bleeding disorders Treatment Market by Region, 2020β2027 (USD Million)
Table 4 Global Bleeding disorders Treatment Market by Type, 2020β2027 (USD Million)
Table 5 Global Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 6 Global Bleeding disorders Treatment Market by Treatment, 2020β2027 (USD Million)
Table 7 Global Bleeding disorders Treatment MarketEnd-users, 2020β2027 (USD Million)
Table 8 North America: Bleeding disorders Treatment Market by Type, 2020β2027 (USD
Million)
Table 9 North America: Bleeding disorders Treatment Market by Drug Class, 2020β2027 (USD Million)
Table 10 North America: Bleeding disorders Treatment Market by Treatment, 2020β2027 (USD Million)
Table 11 North America: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 12 US: Bleeding disorders Treatment Market by Type, 2020β2027 (USD Million)
Table 13 US: Bleeding disorders TreatmentMarketby Drug Class, 2020β2027 (USD Million)
Table 14 US: Bleeding disorders TreatmentMarketby Treatment, 2020β2027 (USD Million)
Table 15 US: Bleeding disorders Treatment Market by End-users, 2020β2027 (USD Million)
Table 16 Canada: Bleeding disorders Treatment Market by Type, 2020β2027 (USD Million)
Table 17 Canada: Bleeding disorders Treatment Market by Drug Class, 2020β2027 (USD Million)
Table 18 Canada: Bleeding disorders Treatment Market by Treatment, 2020β2027 (USD Million)
Table 19 Canada: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 20 South America: Bleeding disorders Treatment Market by Type, 2020β2027 (USD Million)
Table 21 South America: Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 22 South America: Bleeding disorders Treatment by Treatment, 2020β2027 (USD Million)
Table 23 South America: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 24 Europe: Bleeding disorders Treatment by Type, 2020β2027 (USD Million)
Table 25 Europe: Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 26 Europe: Bleeding disorders Treatment Market, by Treatment, 2020β2027 (USD Million)
Table 27 Europe: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 28 Western Europe: Bleeding disorders Treatment by Type, 2020β2027 (USD Million)
Table 29 Western Europe: Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 30 Western Europe: Bleeding disorders Treatment by Treatment, 2020β2027 (USD Million)
Table 31 Western Europe: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 32 Eastern Europe: Bleeding disorders Treatment by Type, 2020β2027 (USD Million)
Table 33 Eastern Europe Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 34 Eastern Europe Bleeding disorders Treatment by Treatment, 2020β2027 (USD Million)
Table 35 Eastern Europe: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 36 Asia-Pacific: Bleeding disorders Treatment by Type, 2020β2027 (USD Million)
Table 37 Asia-Pacific: Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 38 Asia-Pacific: Bleeding disorders Treatment by Treatment, 2020β2027 (USD Million)
Table 39 Asia-Pacific: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
Table 40 Middle East & Africa: Bleeding disorders Treatment by Type, 2020β2027 (USD Million)
Table 41 Middle East & Africa Bleeding disorders Treatment by Drug Class, 2020β2027 (USD Million)
Table 42 Middle East & Africa: Bleeding disorders Treatment Market, by Treatment, 2020β2027 (USD Million)
Table 43 Middle East & Africa: Bleeding disorders Treatment by End-users, 2020β2027 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Bleeding disorders Treatment
Figure 3 Segmentation Market Dynamics for Global Bleeding disorders Treatment
Figure 4 Global Bleeding disorders Treatment Industry Market Share, by Type, 2020
Figure 5 Global Bleeding disorders Treatmentby End-users, 2020β2027 (USD Million)
Figure 6 Global Bleeding disorders Treatment MarketShare, by Region, 2020
Figure 7 North America: Bleeding disorders Treatment Market Share, by Country, 2020
Figure 8 Europe: Bleeding disorders Treatment Market Share, by Country, 2020
Figure 9 Asia-Pacific: Bleeding disorders TreatmentMarket Share, by Country, 2020
Figure 10Middle East & Africa: Bleeding disorders TreatmentMarket Share, by Country, 2020
Figure 11Global Bleeding disorders Treatment: Company Market Share Analysis, 2020 (%)
Figure 12Shire Plc.: Key Financials
Figure 13Shire Plc: Segmental Revenue
Figure 14 Shire Plc: Geographical Revenue
Figure 15Bayer Pharmaceuticals: Key Financials
Figure 16Bayer Pharmaceuticals: Segmental Revenue
Figure 17Bayer Pharmaceuticals: Geographical Revenue
Figure 18Novo Nordisk A/S: Key Financials
Figure 19Novo Nordisk A/S: Segmental Revenue
Figure 20Novo Nordisk A/S: Geographical Revenue
Figure 21Pfizer Inc.: Key Financials
Figure 22Pfizer Inc.: Segmental Revenue
Figure 23Pfizer Inc.: Geographical Revenue
Figure 24Biogen Idec: Key Financials
Figure 25Biogen Idec: Segmental Revenue
Figure 26Biogen Idec: Geographical Revenue
Figure 27CSL Behring: Key Financials
Figure 28 CSL Behring: Segmental Revenue
Figure 29 CSL Behring: Geographical Revenue
Figure 30Grifols: Key Financials
Figure 31Grifols: Segmental Revenue
Figure 32Grifols: Geographical Revenue
Figure 33Octapharma: Key Financials
Figure 34Octapharma: Segmental Revenue
Figure 35Octapharma: Geographical Revenue
Figure 36Sun Pharmaceutical Industries Ltd.: Key Financials
Figure 37 Sun Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 38Sun Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 39BDI Pharma: Key Financials
Figure 40BDI Pharma: Segmental Revenue
Figure 41BDI Pharma: Geographical Revenue
Figure 42Ferring Pharmaceuticals: Key Financials
Figure 43 Ferring Pharmaceuticals: Segmental Revenue
Figure 44 Ferring Pharmaceuticals: Geographical Revenue
Figure 45 Others: Key Financials
Figure 46 Others: Segmental Revenue
Figure 47 Others: Geographical Revenue